Department of Internal Medicine, University Hospital Gasthuisberg, University of Leuven, Belgium.
Aliment Pharmacol Ther. 2010 May;31(10):1123-31. doi: 10.1111/j.1365-2036.2010.04259.x. Epub 2010 Feb 8.
Little is known about the physiological role of the endocannabinoid system in the regulation of the motility and the sensitivity of the stomach. Endocannabinoid system dysfunction has been hypothesized to contribute to the control of food intake and the pathogenesis of functional dyspepsia.
To study the influence of rimonabant, the endocannabinoid 1 (CB1) receptor antagonist, on gastric sensorimotor function in healthy controls.
After 4 days of pre-treatment with rimonabant 20 mg/day or placebo, 12 healthy volunteers (mean age 34 +/- 12 years, six men) participated in a placebo-controlled, double-blind, randomized, crossover study with a gastric barostat assessment of gastric sensitivity to distension, gastric compliance, gastric accommodation and phasic motility on day 3 and a liquid nutrient challenge test on day 4.
Rimonabant did not influence gastric compliance and sensitivity to distension. The meal-induced gastric accommodation reflex was significantly inhibited by rimonabant (154.3 +/- 30.9 vs. 64.3 +/- 32.4 mL, P = 0.02). Rimonabant did not affect maximal nutrient tolerance or meal-related symptoms during the satiety drinking test.
Endocannabinoids acting on the CB1 receptor are involved in the control of gastric accommodation in man.
内源性大麻素系统在调节胃动力和敏感性方面的生理作用知之甚少。内源性大麻素系统功能障碍被认为与控制食物摄入和功能性消化不良的发病机制有关。
研究内源性大麻素 1（CB1）受体拮抗剂利莫那班对健康对照者胃感觉运动功能的影响。
在接受利莫那班 20 毫克/天或安慰剂预处理 4 天后，12 名健康志愿者（平均年龄 34 +/- 12 岁，6 名男性）参加了一项安慰剂对照、双盲、随机、交叉研究，在第 3 天使用胃测压法评估胃对扩张的敏感性、胃顺应性、胃容纳和相位运动，第 4 天进行液体营养挑战试验。
利莫那班不影响胃顺应性和对扩张的敏感性。利莫那班显著抑制了进餐诱导的胃容纳反射（154.3 +/- 30.9 与 64.3 +/- 32.4 毫升，P = 0.02）。利莫那班不影响最大营养耐受性或在饱腹感饮用量表测试中的进餐相关症状。
作用于 CB1 受体的内源性大麻素参与了人类胃容纳的控制。
